Hypercalcemia Treatment - Global Strategic Business Report

Global Hypercalcemia Treatment Market to Reach $38.3 Billion by 2030

The global market for Hypercalcemia Treatment estimated at US$18.7 Billion in the year 2022, is projected to reach a revised size of US$38.3 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2022-2030. Bisphosphonates, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$25.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Calcitonin segment is readjusted to a revised 8.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $5.7 Billion, While China is Forecast to Grow at 8.6% CAGR

The Hypercalcemia Treatment market in the U.S. is estimated at US$5.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 7.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Select Competitors (Total 38 Featured) -

• AbbVie, Inc.
• Amgen, Inc.
• DiaSorin SpA
• Fujirebio Europe NV
• Kyowa Hakko Kirin Co., Ltd.
• Merck & Co., Inc.
• Novartis AG
• Opko Health, Inc.
• Rockwell Medical

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year